Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$16.01 USD

16.01
1,048,219

0.00 (0.00%)

Updated May 16, 2024 04:00 PM ET

After-Market: $16.00 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

National Vision (EYE) Rides on Robust Growth Across All Lines

National Vision (EYE) continues to register strong segmental performances.

Teleflex Hits New 52-Week High: What's Driving the Rally?

Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.

Thermo Fisher Rides on New Product Suite, Currency Woes Stay

Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.

Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod

Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

Here's Why You Should Add NuVasive Stock to Your Portfolio

Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.

Edwards (EW) Rides on Innovation Despite Regulatory Issues

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.

Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises

Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.

GNC Holdings Launches Energy Drink With Natural Extracts

GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.

NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance

Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.

EYE vs. AHCO: Which Stock Should Value Investors Buy Now?

EYE vs. AHCO: Which Stock Is the Better Value Option?

Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

Medtronic's (MDT) Brain Therapies Device Receives FDA Approval

Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.

Medtronic Acquires Klue to Strengthen Diabetes Management Arm

Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.

Globus Medical Rides on New Product Menu, U.S. Spine Business

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Boston Scientific Hits New 52-Week High: What's Driving it?

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)

Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.

CVS Health Rides on Aetna Prospects, Strong Selling Season

CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.

Omnicell-Huron Sign a Pact for Outcome-Based Expert Services

Omnicell (OMCL) partners Huron to provide customers with committed expertise.

Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry

Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.

Globus Medical Hits 52-Week High: What's Driving the Stock?

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.